oregon_prescription_drug_price_transparency_progra.pdf
Boehringer Ingelheim Reports Spevigo Price to Oregon's Drug Program
Trusted by teams at
Description
Boehringer Ingelheim Pharmaceuticals Inc. reported $51,133 WAC for Spevigo under Oregon's specialty drug reporting program.
Contract Details
Contract Amount
$51,133 (WAC price for Spevigo)
Vendor
BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Agency
Oregon HA | Sustainable Health Care Cost Growth Target, OR
Contract Type
SUPPLIES
Document Date
December 1, 2023
More from BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Related Contracts
Issuing Agency
Oregon HA | Sustainable Health Care Cost Growth Target
State
Salem, OR
More from Oregon HA | Sustainable Health Care Cost Growth Target
sustainable_health_care_cost_growth_target_advisor.pdf
sustainable_health_care_cost_growth_target_advisor.pdf
sustainable_health_care_cost_growth_target_advisor.pdf
oregon_health_authority_health_care_cost_growth_tr.pdf
oregon_health_authority_health_care_cost_growth_tr.pdf
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.